Record 048 · Therapeutics · 2015
50%15.48.X
BioAge Labs
BioAge Labs
“Aging drugs sourced from human biobanks, now a public company.”
Kristen Fortney’s BioAge mines human aging cohorts for targets (apelin, NLRP3, and others) and ran them toward muscle and metabolic disease.
A therapeutics company that had to face the market.
Series B+. Filed from the Top Tier Impact landscape.
- Human cohort targets
- Azelaprag / NLRP3
- Public listing
The biobank as a pipeline.
